Catabasis Renames As Astria Therapeutics With New Disease Focus
Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is looking to hit the reset button with a new name and focus. Catabasis has been…
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc.
Wedbush Initiates Coverage On Catabasis Pharmaceuticals with Outperform Rating, Announces Price Target of $16
Wedbush analyst Laura Chico initiates coverage on Catabasis Pharmaceuticals (NASDAQ:CATB) with a Outperform rating and announces Price Target of $16.
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 124 companies hit new 52-week highs.
HC Wainwright & Co. Upgrades Catabasis Pharmaceuticals to Buy, Announces $13 Price Target
HC Wainwright & Co. analyst Joseph Pantginis upgrades Catabasis Pharmaceuticals (NASDAQ:CATB) from Neutral to Buy and announces $13 price target.
60 Biggest Movers From Yesterday
Gainers
Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)